Aevi Genomic Medicine Inc
GNMX
GNMX was delisted on the 3rd of February, 2020.
51 hedge funds and large institutions have $54.9M invested in Aevi Genomic Medicine Inc in 2015 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 25 increasing their positions, 8 reducing their positions, and 8 closing their positions.
3,478% more call options, than puts
Call options by funds: $322K | Put options by funds: $9K
213% more repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 8
45% more capital invested
Capital invested by funds: $38M → $54.9M (+$16.9M)
6% less funds holding
Funds holding: 54 → 51 (-3)
38% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Broadfin Capital
New York
|
+$3.34M |
| 2 |
QF
QVT Financial
New York
|
+$2.07M |
| 3 |
Jennison Associates
New York
|
+$1.28M |
| 4 |
Northern Trust
Chicago,
Illinois
|
+$984K |
| 5 |
BGA
Belmont Global Advisors
Dallas,
Texas
|
+$921K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
-$2.85M |
| 2 |
Renaissance Technologies
New York
|
-$266K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$120K |
| 4 |
VOYA Investment Management
Atlanta,
Georgia
|
-$87K |
| 5 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
-$40K |
GNMX Hedge Fund Activity: Q3 2015 in Review
51 of the 3,582 institutional investors tracked by Wall St. Rank reported a position in Aevi Genomic Medicine Inc (GNMX) for Q3 2015, worth a combined $54.9M — up 45% from $38M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of GNMX and 5 opened new positions — a net loss of 3 holders — while 8 trimmed existing stakes and 25 added.
The largest buyer was Broadfin Capital, adding an estimated $3.34M. The largest seller was Perceptive Advisors, exiting entirely with an estimated $2.85M sold.
- 51 institutional investors held Aevi Genomic Medicine Inc (GNMX) as of Q3 2015, down from 54 in Q2 2015.
- Funds reported $54.9M of Aevi Genomic Medicine Inc stock for Q3 2015, up 45% quarter-over-quarter.
- 5 funds opened new Aevi Genomic Medicine Inc positions in Q3 2015 and 8 closed out, a net change of -3 holders.
- The largest Aevi Genomic Medicine Inc buyer in Q3 2015 was Broadfin Capital, an estimated $3.34M added.
- The largest Aevi Genomic Medicine Inc seller in Q3 2015 was Perceptive Advisors, an estimated $2.85M sold.
Based on aggregated 13F filings for Q3 2015.